News >

Future of AYA ALL Research Should Include Eliminating MRD, Treating High-Risk Patients

Jason Harris
Published: Thursday, Sep 13, 2018

Wendy Stock, MD,

Wendy Stock, MD
Following survival improvements in the field of adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), researchers must turn their focus to lowering toxicity, delivering treatment to high-risk subgroups, eliminating minimal residual disease (MRD) early in treatment, and addressing the unique psychosocial and economic challenges facing this often-overlooked patient population, according to Wendy Stock, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x